Bioequivalency Study of Zidovudine Under Fasting Conditions

Completed · Not applicable

Conditions studied: HIV Infections

In brief

The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

Key facts

Study ID

NCT00602550

Run by

Roxane Laboratories

People needed

52

Starts

2003-06-01

Expected to finish

2003-06-01

Last updated by the study team

2018-01-23

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• No clinically significant abnormal findings on physical exam, medical history, or clinical laboratory findings during screening.

You may not qualify if…

• Allergic or adverse responses to zidovudine or any other comparable or similar products.
• Participation in clinical trial within 30 days of study initiation.
• Positive blood screen for HIV, Hepatitis B and C.

Where it is running

• CEDRA Clinical Research — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.